



# Optical control of purinergic signaling

Tao Wang<sup>1,2</sup> · Henning Ulrich<sup>1,3</sup> · Alexey Semyanov<sup>4,5</sup> · Peter Illes<sup>1,6</sup> · Yong Tang<sup>1,2</sup>

Received: 1 November 2020 / Accepted: 7 June 2021 / Published online: 22 June 2021  
© The Author(s) 2021

## Abstract

Purinergic signaling plays a pivotal role in physiological processes and pathological conditions. Over the past decades, conventional pharmacological, biochemical, and molecular biology techniques have been utilized to investigate purinergic signaling cascades. However, none of them is capable of spatially and temporally manipulating purinergic signaling cascades. Currently, optical approaches, including optopharmacology and optogenetic, enable controlling purinergic signaling with low invasiveness and high spatiotemporal precision. In this mini-review, we discuss optical approaches for controlling purinergic signaling and their applications in basic and translational science.

**Keywords** Purinergic signaling · P1 receptors · P2X receptors · P2Y receptors · Optopharmacology · Caged compounds · Photoswitchable compounds · Optogenetics

## Introduction

The concept of purinergic signaling was first proposed in 1972 when Burnstock stated that adenosine triphosphate (ATP) not only participates in the intracellular storage of energy but is also an extracellular transmitter/signaling molecule [13]. Subsequently, a range of purinergic receptors (Rs) was cloned and characterized: four types of P1Rs

(G protein-coupled receptors, A<sub>1</sub>, A<sub>2A</sub>, A<sub>2B</sub>, A<sub>3</sub>) [21], seven types of P2XRs (ligand-gated cationic channels, P2X<sub>1-7</sub>), and eight types of P2YRs (G protein-coupled receptors, P2Y<sub>1, 2, 4, 6, 11-14</sub>) [1, 30, 31, 33] (Fig. 1A). Both P1Rs and P2YRs are G protein-coupled receptors and consist of seven transmembrane (TM) proteins. However, P1Rs are selectively activated by extracellular adenosine, which is obtained by dephosphorylation of its precursor entities: ATP, adenosine diphosphate (ADP), and adenosine monophosphate (AMP) [9], whereas P2YRs are activated by ATP, as well as by ADP [31]. In contrast with these G protein-coupled receptors, P2XRs are ligand-gating ion channels and characterized by two transmembrane (TM1 and TM2) proteins. P2XRs are only sensitive to ATP and undergo a conformational change in the channel upon ATP activation [30]. These purinergic receptors are widely distributed throughout the body and show great diversity in functions. If we want a high-resolution view of how individual purinergic receptor carries out specific tasks, we need high-resolution tools for controlling the activity of these receptors. In the past, many pharmacological drugs selectively targeting purinergic receptor subtypes have been developed, but they do not distinguish between the same purinergic receptors expressed in subtypes of neurons or different brain regions. Thus, the lack of tissue-specific selectivity may trigger undesirable side effects. For instance, therapeutic use of the A<sub>2A</sub>R agonist, regadenoson, is always associated with off-side effects, including headache, nausea, chest discomfort, or dizziness

✉ Peter Illes  
peter.illes@medizin.uni-leipzig.de

✉ Yong Tang  
tangyong@cdutcm.edu.cn

Tao Wang  
wangtao@stu.cdutcm.edu.cn

<sup>1</sup> International Collaborative Centre On Big Science Plan for Purinergic Signalling, Chengdu University of Traditional Chinese Medicine, Chengdu, China


<sup>2</sup> Acupuncture and Chronobiology Key Laboratory of Sichuan Province, Chengdu, China

<sup>3</sup> Department of Biochemistry, Institute of Chemistry, University of São Paulo, São Paulo, Brazil

<sup>4</sup> Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia

<sup>5</sup> Sechenov First Moscow State Medical University, Moscow, Russia

<sup>6</sup> Rudolf Boehm Institute for Pharmacology and Toxicology, University of Leipzig, Leipzig, Germany



**Fig. 1** Three types of optical approaches may control purinergic signaling. **A** The concept of purinergic signaling. ATP is sequentially degraded to ADP, AMP, ADP, and adenosine by ecto-ATPase (CD39) and 5'-nucleotidase (CD73). Purinergic receptors have been classified into three types: P1Rs (A<sub>1</sub>, A<sub>2A</sub>, A<sub>2B</sub>, A<sub>3</sub>) that are only sensitive to adenosine, P2XRs (P2X<sub>1-7</sub>) which are selectively activated by ATP, and P2YRs (P2Y<sub>1,2,4,6,11-14</sub>) which are activated by both ATP, ADP, and further nucleotides. P2XRs are characterized by two transmembrane spanning regions (TM1 and TM2) and a large extracellular loop, while P2Ys and P1Rs consist of seven transmembrane spanning regions. **B** Three types of optical approaches for controlling purinergic

signaling. **a** Caged compounds: Photolysis of caged ATP, caged agonist of P2Y<sub>1</sub>R and P2Y<sub>12</sub>R, and caged A<sub>2A</sub>R antagonist enables the rapid control of purinergic receptors by light. **b** Photoswitchable compounds: P2XRs channels can be opened or closed by introducing photoswitches to a defined site of them. **c** Optogenetics: Optogenetic control of A<sub>2A</sub>R and P2Y<sub>1</sub>R can be achieved by the introduction of genetically encoded photosensitive opsin. A total of 593 nm light in NpHR-A<sub>2A</sub>R enables inhibiting A<sub>2A</sub>R signaling while 473 nm light in ChR2-A<sub>2A</sub>R activates signaling of this receptor subtype. A total of 473 nm light excitation of the P2Y<sub>1</sub>R-ChR2 activates P2Y<sub>1</sub>R signaling

(available at <http://clinicaltrials.gov>). Moreover, the temporal precision of these drugs is limited by the diffusion, transport, or metabolism of active compounds. Although genetic tools enable the knock-in or knock-out of purinergic receptor subtype genes in defined subtypes of neurons or brain regions, they have inherent limitations due to the lack of spatial precision. The lack of spatiotemporal precision prevents researchers from fully understanding the role of purinergic signaling in both physiological and pathological conditions and further designing effective therapies. Therefore, novel approaches with the ability of quickly and precisely controlling purinergic signaling are needed.

Recently, optical approaches to control receptor and channel activities by light are transforming neuroscience research [35, 50, 54]. The use of light can be advantageous

as light is non-invasive, can be modulated in its intensity within femtoseconds, and can be delivered in a highly controlled manner in space and time, which can overcome some of the shortcomings of conventional techniques. Two main types of optical approaches have been used for the control of purinergic signaling: optopharmacology and optogenetics.

Optopharmacology, also known as photopharmacology, refers to confer light sensitivity to a freely diffusible ligand, rather than to a target protein [50]. Since it first emerged in the 1970s when several photoreactive ligands were synthesized [7, 36], optopharmacology has boomed in neuroscience in recent years. The simplest and most widely used photosensitive chemicals are caged compounds, which are chemically modified with

photoremovable protecting groups and is biologically inert before photolysis. Irradiation breaks the chemical modifications and thus results in a concentration jump of biologically active molecules in a time-dependent manner. The first attempt to synthesized caged compound dates back to 1978, when Kaplan and coworkers synthesized NPE (P3-1-(2-nitro)phenyl-ethyl), the first photoremovable protecting group, to modify ATP [32]. Subsequently, various photoremovable protecting groups, such as P3-3',5'-dimethoxybenzoic acid (DMB) [58] and P3-[1-(4,5-dimethoxy-2-nitrophenyl)ethyl] (DMNPE) [8], have been synthesized. To date, many biomolecules or second messengers, including calcium [2], neurotransmitters [47], nucleotides [8], and peptides [39], have been caged to control cellular chemistry and physiology. However, the process of photolysis is irreversible due to the light-induced break of chemical bonds. Conversely, photoswitchable compounds enable to light-control receptors reversibly. When the target receptors are chemically attached with synthetic photoswitchable compounds, light can induce conformational changes between cis and trans isomer of the photoswitchable compounds and thereby trigger a reversible on–off control of these receptors [29, 63]. These synthetic photoswitchable compounds allow for the spatiotemporal and reversible control of a wide range of biological targets, including ion channels [6], transporters [15], G protein-coupled receptors [23], and enzymes [43], and also show huge potential in clinical treatment [19, 59].

Optogenetics is another powerful optical technique. The term optogenetics was first introduced by Deisseroth and colleagues in 2006 when they reported that the expression of microbial opsin genes in mammalian neurons resulted in the precise control of neural activity in a millisecond timescale [10]. Over the past decade, optogenetics was rapidly adopted to photoactivation and photoinhibition of cellular activities and probe neuronal functions [16]. Optogenetics strategy relies on the genetical modification of endogenous proteins with microbial opsin, including light-driven ion pumps, such as bacteriorhodopsins (BRs) and halorhodopsins (HRs), and ion channels, such as channelrhodopsins (ChRs) [55]. This contrasts with optopharmacology, in which chemical synthesis was necessary. In addition, a novel class of genetically encoded optogenetics tools, optoXRs, which are chimeric proteins coupled to different intracellular G protein-initiated signaling cascades, has been developed for selective control of Gs and Gq signaling [56].

Here, we provide a review which summarizes the applications of optical approaches in controlling purinergic signaling and their applications in investigating purinergic signaling and also discuss important considerations when applying to manipulate purinergic signaling.

## Optopharmacology for controlling purinergic signaling

In the past few years, chemists have developed various photosensitive drugs for the control of purinergic receptors, including caged compounds and photoswitchable compounds. Compared to conventional agonists or antagonists, such photochemicals offer great temporal and spatial precision. First, fast photolysis of caged compounds or light switching by photoswitchable compounds allows the control of purinergic receptors at a millisecond timescale, which is consistent with the temporal dynamics of endogenous cellular activity. Second, light delivered by the illumination device can be focused onto targeted areas of interest. Therefore, the spatiotemporal control of purinergic receptors by photosensitive chemicals permits a real-time link between the activity of purinergic receptors and a defined biological or physiological response in cells or living organisms.

### Caged compounds

Caged ATP is widely utilized to control the activation of purinergic receptors (Fig. 1a). When added to the bath with a micropipette, caged ATP is biologically inert with the absence of light stimulation while it could produce free ATP within milliseconds [20]. With this strategy, Zemelman and coworkers found that photostimulation ( $26 \text{ mW}\cdot\text{mm}^{-2}$  of optical power at wavelengths  $< 400 \text{ nm}$ ) of DMNPE-caged ATP could quickly activate heterologously expressed P2X<sub>2</sub>Rs in hippocampal neurons and evoke membrane potentials of these neurons in a time-dependent manner [62]. DMNPE-caged ATP was also employed to control the activation of exogenous P2X<sub>3</sub>Rs, which allows for assessing the fast activation kinetics of the whole-cell P2X<sub>3</sub>R-current [25]. Further, Fischer et al. found that photolysis of NPE-caged ATP with a 405 nm laser enabled the fast activation of P2Y<sub>1</sub>Rs in mitral cells, thereby resulting in the increased neuronal network activity in the olfactory bulb, which contributed to our understanding of the physiological role of P2Y<sub>1</sub>Rs in the central nervous system [20].

Recently, caged purinergic receptor agonists and antagonists have also been developed, enabling the control of specific purinergic receptor subtypes. For example, Gao and coworkers synthesized MRS2703, a caged form of a potent dual agonist of P2Y<sub>1</sub>Rs and P2Y<sub>12</sub>Rs (2-methylthio-ADP, (2-MeSADP)) [22] (Fig. 1a). It is inactive at both P2Y<sub>1</sub>Rs and P2Y<sub>12</sub>Rs prior to irradiation. However, upon irradiation at 360 nm for 5 s, photo-uncaging MRS2703 in washed human platelets could activate P2Y<sub>1</sub>Rs and P2Y<sub>12</sub>Rs expressed on the surface of platelets and facilitated the platelets aggregation. Another example is the synthesis of caged

$A_{2A}R$  antagonist MRS7145 [57] (Fig. 1a). In cultured cells transfecting with  $A_{2A}Rs$ , photo-uncaging MRS7145 with 405 nm light rapidly activated  $A_{2A}Rs$  and preclude  $A_{2A}Rs$  agonist-induced cyclic adenosine monophosphate (cAMP) accumulation. Further, after intraperitoneal injection of MRS7145 into mice, irradiation (405 nm) in the dorsal striatum of mice could significantly induce hyperlocomotion and counteracted haloperidol-induced catalepsy and pilocarpine-induced tremor [57]. These two examples also indicated that the photocontrol of purinergic receptors with caged compounds could provide a new strategy for clinical treatment.

Although photolysis of caged compounds has proven useful for controlling purinergic receptors and dissecting the functions of different purinergic receptors, it also has some limitations. First, as the synthesis of caged compounds is usually complex, biologists are restricted to the few caged compounds that are commercially available or they must collaborate with academic laboratories that synthesize caged compounds [17, 18]. Second, it is still unclear whether the by-products (the cleavage product of the photoremovable protecting group) generate unpredictable cellular or extracellular responses. Considering this, it should be confirmed that these by-products are biologically inert and non-toxic before the experiments [34]. Third, the irreversible nature due to light-induced break of chemical bonds becomes the major limitation, for instance, when one seeks to investigate the opening and closing mechanism of  $P2XRs$ .

## Photoswitchable compounds

The photolysis of caged compounds is an irreversible process. Photoswitchable compounds, in contrast, can be used to reversibly manipulate a wide range of biological targets, including G protein-coupled receptors, ion channels, transporters, and enzymes [5, 54, 63]. Light induces conformational changes in these photoswitchable compounds and thereby controls targeted receptors in a time-dependent manner.

Photoswitchable compounds have been successfully employed to optically control purinergic receptors. In two independent groups, photoswitchable compounds, named 4,4'-bis(maleimido)azobenzene (BMA) and maleimide ethylene azobenzene trimethyl ammonium (MEA-TMA), have been synthesized and then were covalently tethered into the outer ends of transmembrane helices of the  $P2X_2Rs$  at residue P329C and I328C, respectively [12, 35]. Light-controlled toggling between cis and trans isomers of azobenzene acts to bring the subunits closer or further apart, thus closing or opening the channel. Importantly, they found that rapid opening of  $P2X_2R$  channels allowed permeation of small cations, such as sodium and calcium ions, but not to chloride ions, indicating that tethered photoswitchable compounds did not alter cation selectivity of the  $P2X_2R$  channel [35].

Similarly, photoswitching has also been applied to manipulate  $P2X_3Rs$  and heteromeric  $P2X_{2/3}Rs$ . In  $P2X_3Rs$  with P320C mutation, after treatment with BMA, the light at 440 nm rapidly evokes desensitizing currents while light at 360 nm switches off these currents (Fig. 1b) [12]. These light-activated currents are like that activated by a maximal concentration of ATP. The heteromeric  $P2X_{2/3}R$  channels, which is formed by two  $P2X_3R$ [P320C] subunits and one  $P2X_2R$  subunit, also can be opened and closed by light illumination. This finding indicates that conformational change between only two  $P2X_3Rs$  subunits is sufficient for  $P2X_{2/3}R$  channel opening [12].

A recent study using photoswitchable tweezer to photo-control  $P2X_2R$  has contributed to our understanding of the gating mechanism (Habermacher et al., 2016). These photoswitchable tweezers hold strong ability to reveal details of how the subunits move to open or close the  $P2X_2R$  channel's pore, which overcomes the shortcomings of X-ray crystallography. This strategy entailed the use of a synthesized maleimide azobenzene maleimide (MAM), a photoswitchable azobenzene cross-linker carrying two sulfhydryl-reactive maleimides known to cross-link pairs of an engineered cysteine residue. When attached between I328C from one subunit and S345C from another in  $P2X_2R$ , the cis isomer of MAM induced pore opening by a 525 nm light and the trans isomer induced a closing state by a 365 nm light (Fig. 1b). Combining the photoswitching with computational studies, they further found that the extent of the outer pore expansion is significantly reduced compared to the ATP-bound structure, and the inner and outer ends of adjacent pore-lining helices come closer during opening, likely through a hinge-bending motion.

Photoswitchable tweezers also provide useful molecular rulers to probe the permeation mechanism of  $P2XRs$ . Harkat et al. synthesized a shorter, however, more rigid photoswitchable tweezer, named MAM-2 [26]. When this tweezer was covalently attached to residues I328 and S345 of  $P2X_2R$ , 365 nm light at these  $P2X_2Rs$  permits the flow of large synthetic cation, N-methyl-D-glucamine (NMDG<sup>+</sup>), as well as large natural cation, spermidine. As spermidine is known to modulate a number of ion channels, including synaptic N-methyl-D-aspartate (NMDA) receptors [44], the permeability of the  $P2X_2Rs$  for large cations offers new insights into the physiological function of  $P2X_2Rs$ .

These photoswitchable compounds can be successfully employed to manipulate the opening and closing state of  $P2XRs$  and help boost our understanding of their permeation and gating mechanisms. This is achieved by the photoconversion of azobenzenes, which can reversibly switch between a cis form and a trans configuration using two different wavelengths of light, classically near-ultraviolet (360–400 nm) and blue-green light (480–550 nm) [54, 63]. However, the toxicity of azobenzenes, which may stem from

cleavage into carcinogenic aromatic amines and metabolic oxidation of amine-bearing azobenzenes to toxic species [41, 60], limits its application in vivo. In addition, the complete recovery of conformational change is not possible due to incomplete cis to trans photoisomerization [11, 40]. However, the recent evidence that silver nanowire antennas enhance the conversion efficiency from around 20 to up to 85% [61] may provide a new strategy to increase the yield of cis/trans isomers. Further, it is entirely possible that photoswitchable compounds could be extended to photocontrol other P2XRs since these P2XRs share similar structures and gating mechanisms.

## Optogenetics for controlling purinergic receptors signaling

Although optopharmacological strategies have proven useful to control purinergic receptors, they have inherent limitations to be used in vivo. Optogenetics overcomes these limitations and has been successfully utilized in vivo. Furthermore, it also enables to control purinergic receptors signaling with spatial and temporal precision, which permits to investigate the behavioral responses upon the control of purinergic receptors signaling.

With the technical advance in opto- $A_{2A}R$  and transgenic strategy, optogenetics has been successfully applied to activate or inhibit  $A_{2A}R$  signaling by light. The opto- $A_{2A}R$  is synthesized by retaining the extracellular and transmembrane domains of rhodopsin (conferring light sensitivity and eliminating the binding pockets of adenosine) and replacing the intracellular domain of rhodopsin with that of the  $A_{2A}R$  (conferring specific  $A_{2A}R$  signaling) [37]. When opto- $A_{2A}R$  is cloned into a viral vector carrying with cell-type-specific promoter, it can be typically introduced into specific subtype neurons in the targeted brain area by stereotaxic microinjection. After 2–3 weeks for the expression of opto- $A_{2A}R$  construct in the brain, 473 nm laser light could activate opto- $A_{2A}R$  and recruit  $A_{2A}R$  signaling. As for transgenic strategy,  $A_{2A}R$ -cre mice, in which the expression of cre recombinase is under the control of  $A_{2A}R$  gene regulatory elements, are constructed. The use of a cre-dependent viral vector carrying ChR2 into  $A_{2A}R$ -cre mice is capable of activating  $A_{2A}R$  signaling by 473 nm light, while the application of a cre-dependent viral vector transforming NpHR into  $A_{2A}R$ -cre mice enables inhibiting  $A_{2A}R$  signaling by 593 nm light [28] (Fig. 1c). With these strategies, Oishi and coworkers found that photoactivation of  $A_{2A}R$  signaling in the core region of the nucleus accumbens of  $A_{2A}R$ -cre mice induced slow-wave sleep, while such a reaction did not occur when photoactivation was targeted to the shell region of the nucleus accumbens [48]. Hong et al. showed that optogenetic activation of  $A_{2A}R$ -containing indirect medium spiny

projection neurons in the dorsomedial striatum of  $A_{2A}R$ -cre mice reduced ethanol-containing reward-seeking behavior, whereas optogenetic inhibition of these  $A_{2A}R$  neurons reversed this behavior [28]. Similarly, optogenetic activation of  $A_{2A}R$  signaling in the dorsomedial striatum selectively impairs the maintenance and retrieval of spatial working memory, but optogenetic activation of  $A_{2A}R$  signaling in the media prefrontal cortex improves memory maintenance [38]. In addition, optogenetics has also been used to manipulate  $A_{2A}R$  signaling in the hippocampus and striatopallidal pathway, revealing their role in memory and instrumental learning, respectively [27, 37].

Optogenetics has also been utilized to photocontrol P2Y<sub>1</sub>Rs in the vagal nerve. For remote control of P2Y<sub>1</sub>R neurons in the vagal nerve, transgenic P2Y<sub>1</sub>R-ChR2 mice are generated by crossing P2Y<sub>1</sub>R-cre mice with reporter mice containing a cre-dependent ChR2 allele. Focal illumination (473 nm laser) of the nerve trunk or particular nerve branches of P2Y<sub>1</sub>R-ChR2 mice traps breathing in exhalation and does not impact heart rate (Fig. 1c) [14]. Further, Prescott et al. find that vagal P2Y<sub>1</sub>R neurons also engage in an airway defense program. They show that photostimulation (473 nm laser) of P2Y<sub>1</sub>R expressing neurons in the vagal nerve of P2Y<sub>1</sub>R-ChR2 mice evokes a suite of protective reflexes, including apnea, vocal fold adduction, swallowing, and expiratory reflexes [53]. These outcomes suggest that optogenetics also enables a spatial and temporal control of purinergic signaling in peripheral nervous systems.

Clearly, optogenetics is an effective and meaningful tool to control purinergic receptors signaling both in central and peripheral nervous systems. But there are still some issues that are worth mentioning. For instance, it was demonstrated that the introduction of a viral vector for opsin expression could influence the transduction efficiency, tropism, and axonal transport in targeted areas [4, 51]. Meanwhile, opsins in the cells themselves may produce the potential immune response and cause the death of cells [42]. Particularly, surgical implantation of an optical fiber to deliver light to the targeted area produces tissue damage, which limits the application of optogenetics to study large-scale neural networks distributed to different parts of the brain. Although wireless optical equipment has provided an alternative solution [3, 45], optogenetics with low immune response and less invasiveness will allow further control of purinergic signaling and investigate their roles in physiological and pathological conditions.

## Conclusion

As documented above, currently, two distinct types of optical approaches afford powerful and precise manipulation of purinergic signaling (Fig. 1): optopharmacology,

which relies on the synthesis of photosensitive chemicals (including caged and photoswitchable compounds), and optogenetics, which requires the genetic modification of the purinergic receptors. With the use of light, these methods enable fast and precise control of targeted purinergic receptors, such as P2X<sub>2</sub>Rs, P2X<sub>3</sub>Rs, P2X<sub>2/3</sub>Rs, P2Y<sub>1</sub>Rs, P2Y<sub>12</sub>Rs, and A<sub>2A</sub>Rs. They are also employed to explore the permeation and gating mechanisms of P2XR<sub>s</sub>, and the role of adenosine receptors in distinct brain areas. They also offer the potential for defining pharmacological targets more precisely.

Although all three optical strategies have been proved powerful and helpful, there are still some problems that have to be solved. Firstly, the delivery of light to the region of interest often requires invasive surgery. Secondly, long-term light stimulation generates heat that leads to permanent tissue damage and affects cellular excitability [49, 52]. In view of that, we suggest the following two considerations when designing experiments: minimization of light power and duration and carefully planned control experiments that account for off-target effects of light delivery. Further, recent advances in magnetogenetics [46] and ultra-sensitive step-function opsin [24], which provide a minimally invasive approach to precisely manipulate neuronal activity in living animals, may overcome these limitations. Ultimately, we are convinced that the elucidation of physiological function and therapeutic potential of purinergic signaling will be further advanced with the development of more intricate and subtle optical tools.

**Abbreviations** ATP: Adenosine triphosphate; Rs: Purinergic receptors; TM: Transmembrane; ADP: Adenosine diphosphate; AMP: Adenosine monophosphate; NPE: P3-1-(2-nitro)phenylethyl; DMB: P3-3',5'-dimethoxybenzoic acid; DMNPE: P3-[1-(4,5-dimethoxy-2-nitrophenyl)ethyl]; DMACM: 7-(Dimethylamino)coumarin-4-ylmethyl; MRS2703: P1-2(methylthio)adenosyl-P2-(RS)-1-(4,5-dimethoxy-2-nitrophenyl)ethyl pyrophosphate; 2-MeSADP: 2-Methylthio-ADP; MRS7145: (7-(Diethylamino)-2-oxo-2H-chromen-4-yl)methyl (2-(furan-2-yl)-7-(3-(4-methoxyphenyl)propyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-yl)carbamate; SCH442416: 2-(2-Furanyl)-7-[3-(4-methoxyphenyl)propyl]-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine; cAMP: Cyclic adenosine monophosphate; BMA: 4,4'-Bis(maleimido)azobenzene; MEA-TMA: Maleimide ethylene azobenzene trimethyl ammonium; MAM: Maleimide azobenzene maleimide; NMDG<sup>+</sup>: N-methyl-D-glucamine; ChR2: Channelrhodopsin-2; NpHR: Halorhodopsin

**Author contribution** TW, YT, and PI drafted the manuscript. All authors contributed to manuscript revision and have read and approved the submitted version.

**Funding** Our work was supported by National Key R&D Program of China (2019YFC1709101), the Project First-Class Disciplines Development of Chengdu University of Traditional Chinese Medicine (CZYHW1901), São Paulo Research Foundation (FAPESP

2018/07366–4), the National Natural Science Foundation of China (81774437, 81973969), Russian Foundation for Basic Research (RFBR) grant 21–54-53018 for NSFC-RFBR collaboration, and Science and Technology Program of Sichuan Province, China (2019YFH0108).

## Compliance with ethical standards

**Conflict of interest** The authors declare no competing interests.

**Ethical approval** This article does not contain any studies with human participants or animals performed by any of the authors.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

## References

1. Abbracchio MP, Burnstock G (1994) Purinoceptors: are there families of P2X and P2Y purinoceptors? *Pharmacol Ther* 64:445–475. [https://doi.org/10.1016/0163-7258\(94\)00048-4](https://doi.org/10.1016/0163-7258(94)00048-4)
2. Agarwal HK, Janicek R, Chi SH, Perry JW, Niggli E, Ellis-Davies GC (2016) Calcium uncaging with visible light. *J Am Chem Soc* 138:3687–3693. <https://doi.org/10.1021/jacs.5b11606>
3. Anpilov S, Shemesh Y, Eren N, Harony-Nicolas H, Benjamin A, Dine J et al (2020) Wireless optogenetic stimulation of oxytocin neurons in a semi-natural setup dynamically elevates both prosocial and agonistic behaviors. *Neuron* 107:644–655.e647. <https://doi.org/10.1016/j.neuron.2020.05.028>
4. Aschauer DF, Kreuz S, Rumpel S (2013) Analysis of transduction efficiency, tropism and axonal transport of AAV serotypes 1, 2, 5, 6, 8 and 9 in the mouse brain. *PLoS One* 8:e76310. <https://doi.org/10.1371/journal.pone.0076310>
5. Bahamonde MI, Taura J, Paoletta S, Gakh AA, Chakraborty S, Hernando J et al (2014) Photomodulation of G protein-coupled adenosine receptors by a novel light-switchable ligand. *Bioconjug Chem* 25:1847–1854. <https://doi.org/10.1021/bc5003373>
6. Barber DM, Liu SA, Gottschling K, Sumser M, Hollmann M, Trauner D (2017) Optical control of AMPA receptors using a photoswitchable quinoxaline-2,3-dione antagonist. *Chem Sci* 8:611–615. <https://doi.org/10.1039/c6sc01621a>
7. Bartels E, Wassermann NH, Erlanger BF (1971) Photochromic activators of the acetylcholine receptor. *Proc Natl Acad Sci U S A* 68:1820–1823. <https://doi.org/10.1073/pnas.68.8.1820>
8. Bernardinelli Y, Haerberli C, Chatton JY (2005) Flash photolysis using a light emitting diode: an efficient, compact, and affordable solution. *Cell Calcium* 37:565–572. <https://doi.org/10.1016/j.ceca.2005.03.001>
9. Borea PA, Gessi S, Merighi S, Vincenzi F, Varani K (2018) Pharmacology of adenosine receptors: the state of the art. *Physiol Rev* 98:1591–1625. <https://doi.org/10.1152/physrev.00049.2017>

10. Boyden ES, Zhang F, Bamberg E, Nagel G, Deisseroth K (2005) Millisecond-timescale, genetically targeted optical control of neural activity. *Nat Neurosci* 8:1263–1268. <https://doi.org/10.1038/nm1525>
11. Brieke C, Rohrbach F, Gottschalk A, Mayer G, Heckel A (2012) Light-controlled tools. *Angew Chem Int Ed Engl* 51:8446–8476. <https://doi.org/10.1002/anie.201202134>
12. Browne LE, Nunes JP, Sim JA, Chudasama V, Bragg L, Caddick S et al (2014) Optical control of trimeric P2X receptors and acid-sensing ion channels. *Proc Natl Acad Sci U S A* 111:521–526. <https://doi.org/10.1073/pnas.1318582111>
13. Burnstock G (1972) Purinergic nerves. *Pharmacol Rev* 24:509–581
14. Chang RB, Strohlic DE, Williams EK, Umans BD, Liberles SD (2015) Vagal sensory neuron subtypes that differentially control breathing. *Cell* 161:622–633. <https://doi.org/10.1016/j.cell.2015.03.022>
15. Cheng B, Morstein J, Ladefoged LK, Maesen JB, Schjøtt B, Sinning S et al (2020) A photoswitchable inhibitor of the human serotonin transporter. *ACS Chem Neurosci* 11:1231–1237. <https://doi.org/10.1021/acscchemneuro.9b00521>
16. Deubner J, Coulon P, Diester I (2019) Optogenetic approaches to study the mammalian brain. *Curr Opin Struct Biol* 57:157–163. <https://doi.org/10.1016/j.sbi.2019.04.003>
17. Ellis-Davies GC (2007) Caged compounds: photorelease technology for control of cellular chemistry and physiology. *Nat Methods* 4:619–628. <https://doi.org/10.1038/nmeth1072>
18. Ellis-Davies GCR (2020) Useful caged compounds for cell physiology. *Acc Chem Res* 53:1593–1604. <https://doi.org/10.1021/acs.accounts.0c00292>
19. Fajardo O, Friedrich RW (2013) Optopharmacology: a light switch for pain. *Nat Chem Biol* 9:219–220. <https://doi.org/10.1038/nchembio.1203>
20. Fischer T, Rotermund N, Lohr C, Hirnet D (2012) P2Y1 receptor activation by photolysis of caged ATP enhances neuronal network activity in the developing olfactory bulb. *Purinergic Signal* 8:191–198. <https://doi.org/10.1007/s11302-011-9286-z>
21. Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J (2001) International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. *Pharmacol Rev* 53:527–552
22. Gao ZG, Hechler B, Besada P, Gachet C, Jacobson KA (2008) Caged agonist of P2Y1 and P2Y12 receptors for light-directed facilitation of platelet aggregation. *Biochem Pharmacol* 75:1341–1347. <https://doi.org/10.1016/j.bcp.2007.10.037>
23. Gómez-Santacana X, de Munnik SM, Vijayachandran P, Da Costa Pereira D, Bebelman JPM, de Esch IJP et al (2018) Photoswitching the efficacy of a small-molecule ligand for a peptidergic GPCR: from antagonism to agonism. *Angew Chem Int Ed Engl* 57:11608–11612. <https://doi.org/10.1002/anie.201804875>
24. Gong X, Mendoza-Halliday D, Ting JT, Kaiser T, Sun X, Bastos AM et al (2020) An ultra-sensitive step-function opsin for minimally invasive optogenetic stimulation in mice and macaques. *Neuron* 107:38–51.e38. <https://doi.org/10.1016/j.neuron.2020.03.032>
25. Grote A, Boldogkoi Z, Zimmer A, Steinhäuser C, Jabs R (2005) Functional characterization of P2X3 receptors fused with fluorescent proteins. *Mol Membr Biol* 22:497–506. <https://doi.org/10.1080/09687860500370638>
26. Harkat M, Peverini L, Cerdan AH, Dunning K, Beudez J, Martz A et al (2017) On the permeation of large organic cations through the pore of ATP-gated P2X receptors. *Proc Natl Acad Sci U S A* 114:E3786–e3795. <https://doi.org/10.1073/pnas.1701379114>
27. He Y, Li Y, Pu Z, Chen M, Gao Y, Chen L et al (2020) Striatopallidal pathway distinctly modulates goal-directed valuation and acquisition of instrumental behavior via striatopallidal output projections. *Cereb Cortex* 30:1366–1381. <https://doi.org/10.1093/cercor/bhz172>
28. Hong SI, Kang S, Chen JF, Choi DS (2019) Indirect medium spiny neurons in the dorsomedial striatum regulate ethanol-containing conditioned reward seeking. *J Neurosci* 39:7206–7217. <https://doi.org/10.1523/jneurosci.0876-19.2019>
29. Hüll K, Morstein J, Trauner D (2018) vivo photopharmacology. *Chem Rev* 118:10710–10747. <https://doi.org/10.1021/acs.chemrev.8b00037>
30. Illes P, Müller CE, Jacobson KA, Grutter T, Nicke A, Fountain SJ et al (2021) Update of P2X receptor properties and their pharmacology: IUPHAR review 30. *Br J Pharmacol* 178:489–514. <https://doi.org/10.1111/bph.15299>
31. Jacobson KA, Delicado EG, Gachet C, Kennedy C, von Kügelgen I, Li B et al (2020) Update of P2Y receptor pharmacology: IUPHAR review 27. *Br J Pharmacol* 177:2413–2433. <https://doi.org/10.1111/bph.15005>
32. Kaplan JH, Forbush B 3rd, Hoffman JF (1978) Rapid photolytic release of adenosine 5'-triphosphate from a protected analogue: utilization by the Na: K pump of human red blood cell ghosts. *Biochemistry* 17:1929–1935. <https://doi.org/10.1021/bi00603a020>
33. Köles L, Fürst S, Illes P (2007) Purine ionotropic (P2X) receptors. *Curr Pharm Des* 13:2368–2384. <https://doi.org/10.2174/138161207781368747>
34. Lee HM, Larson DR, Lawrence DS (2009) Illuminating the chemistry of life: design, synthesis, and applications of “caged” and related photoresponsive compounds. *ACS Chem Biol* 4:409–427. <https://doi.org/10.1021/cb900036s>
35. Lemoine D, Habermacher C, Martz A, Méry PF, Bouquier N, Diverchy F et al (2013) Optical control of an ion channel gate. *Proc Natl Acad Sci U S A* 110:20813–20818. <https://doi.org/10.1073/pnas.1318715110>
36. Lester HA, Krouse ME, Nass MM, Wassermann NH, Erlanger BF (1979) Light-activated drug confirms a mechanism of ion channel blockade. *Nature* 280:509–510. <https://doi.org/10.1038/280509a0>
37. Li P, Rial D, Canas PM, Yoo JH, Li W, Zhou X et al (2015) Optogenetic activation of intracellular adenosine A2A receptor signaling in the hippocampus is sufficient to trigger CREB phosphorylation and impair memory. *Mol Psychiatry* 20:1481. <https://doi.org/10.1038/mp.2015.43>
38. Li Z, Chen X, Wang T, Gao Y, Li F, Chen L et al (2018) The corticostriatal adenosine A(2A) receptor controls maintenance and retrieval of spatial working memory. *Biol Psychiatry* 83:530–541. <https://doi.org/10.1016/j.biopsych.2017.07.017>
39. Lin Y, Mazo MM, Skaalure SC, Thomas MR, Schultz SR, Stevens MM (2019) Activatable cell-biomaterial interfacing with photocaged peptides. *Chem Sci* 10:1158–1167. <https://doi.org/10.1039/c8sc04725a>
40. Liu M, Jinmei H, Abe H, Ito Y (2010) In vitro selection of a photoresponsive RNA aptamer to hemin. *Bioorg Med Chem Lett* 20:2964–2967. <https://doi.org/10.1016/j.bmcl.2010.02.109>
41. Brown MA, De Vito SC (1993) Predicting azo dye toxicity. *Crit Rev Environ Sci Technol* 23(3):249–324
42. Maimon BE, Diaz M, Revol ECM, Schneider AM, Leaker B, Varela CE et al (2018) Optogenetic peripheral nerve immunogenicity. *Sci Rep* 8:14076. <https://doi.org/10.1038/s41598-018-32075-0>
43. Mogaki R, Okuro K, Aida T (2017) Adhesive photoswitch: selective photochemical modulation of enzymes under physiological conditions. *J Am Chem Soc* 139:10072–10078. <https://doi.org/10.1021/jacs.7b05151>
44. Mony L, Zhu S, Carvalho S, Paoletti P (2011) Molecular basis of positive allosteric modulation of GluN2B NMDA receptors by polyamines. *Embo J* 30:3134–3146. <https://doi.org/10.1038/emboj.2011.203>

45. Neff EP (2017) Another advance in wireless optogenetics. *Lab Anim (NY)* 46:54. <https://doi.org/10.1038/labani.1208>
46. Nimpf S, Keays DA (2017) Is magnetogenetics the new optogenetics? *Embo J* 36:1643–1646. <https://doi.org/10.15252/embj.201797177>
47. Ogelman R, Hwang IW, Oh WC (2020) Cloaked caged glutamate eliminates off-target GABA-A receptor antagonism and opens a new door in neuroscience. *Lab Anim (NY)* 49:177–179. <https://doi.org/10.1038/s41684-020-0555-8>
48. Oishi Y, Xu Q, Wang L, Zhang BJ, Takahashi K, Takata Y et al (2017) Slow-wave sleep is controlled by a subset of nucleus accumbens core neurons in mice. *Nat Commun* 8:734. <https://doi.org/10.1038/s41467-017-00781-4>
49. Owen SF, Liu MH, Kreitzer AC (2019) Thermal constraints on in vivo optogenetic manipulations. *Nat Neurosci* 22:1061–1065. <https://doi.org/10.1038/s41593-019-0422-3>
50. Paoletti P, Ellis-Davies GCR, Mourot A (2019) Optical control of neuronal ion channels and receptors. *Nat Rev Neurosci* 20:514–532. <https://doi.org/10.1038/s41583-019-0197-2>
51. Parr-Brownlie LC, Bosch-Bouju C, Schoderboeck L, Sizemore RJ, Abraham WC, Hughes SM (2015) Lentiviral vectors as tools to understand central nervous system biology in mammalian model organisms. *Front Mol Neurosci* 8:14. <https://doi.org/10.3389/fnmol.2015.00014>
52. Peixoto HM, Cruz RMS, Moulin TC, Leão RN (2020) Modeling the effect of temperature on membrane response of light stimulation in optogenetically-targeted neurons. *Front Comput Neurosci* 14:5. <https://doi.org/10.3389/fncom.2020.00005>
53. Prescott SL, Umans BD, Williams EK, Brust RD, Liberles SD (2020) An airway protection program revealed by sweeping genetic control of vagal afferents. *Cell* 181:574–589.e514. <https://doi.org/10.1016/j.cell.2020.03.004>
54. Reiner A, Levitz J, Isacoff EY (2015) Controlling ionotropic and metabotropic glutamate receptors with light: principles and potential. *Curr Opin Pharmacol* 20:135–143. <https://doi.org/10.1016/j.coph.2014.12.008>
55. Rost BR, Schneider-Warme F, Schmitz D, Hegemann P (2017) Optogenetic tools for subcellular applications in neuroscience. *Neuron* 96:572–603. <https://doi.org/10.1016/j.neuron.2017.09.047>
56. Spangler SM, Bruchas MR (2017) Optogenetic approaches for dissecting neuromodulation and GPCR signaling in neural circuits. *Curr Opin Pharmacol* 32:56–70. <https://doi.org/10.1016/j.coph.2016.11.001>
57. Taura J, Nolen EG, Cabré G, Hernando J, Squarzialupi L, López-Cano M et al (2018) Remote control of movement disorders using a photoactive adenosine A(2A) receptor antagonist. *J Control Release* 283:135–142. <https://doi.org/10.1016/j.jconrel.2018.05.033>
58. Thirlwell H, Corrie JE, Reid GP, Trentham DR, Ferenczi MA (1994) Kinetics of relaxation from rigor of permeabilized fast-twitch skeletal fibers from the rabbit using a novel caged ATP and apyrase. *Biophys J* 67:2436–2447. [https://doi.org/10.1016/s0006-3495\(94\)80730-1](https://doi.org/10.1016/s0006-3495(94)80730-1)
59. Tochitsky I, Helft Z, Meseguer V, Fletcher RB, Vessey KA, Telias M et al (2016) How azobenzene photoswitches restore visual responses to the blind retina. *Neuron* 92:100–113. <https://doi.org/10.1016/j.neuron.2016.08.038>
60. Velema WA, Szymanski W, Feringa BL (2014) Photopharmacology: beyond proof of principle. *J Am Chem Soc* 136:2178–2191. <https://doi.org/10.1021/ja413063e>
61. Yuan Q, Zhang Y, Chen Y, Wang R, Du C, Yasun E et al (2011) Using silver nanowire antennas to enhance the conversion efficiency of photoresponsive DNA nanomotors. *Proc Natl Acad Sci U S A* 108:9331–9336. <https://doi.org/10.1073/pnas.1018358108>
62. Zemelman BV, Nesnas N, Lee GA, Miesenbock G (2003) Photochemical gating of heterologous ion channels: remote control over genetically designated populations of neurons. *Proc Natl Acad Sci U S A* 100:1352–1357. <https://doi.org/10.1073/pnas.242738899>
63. Zhu M, Zhou H (2018) Azobenzene-based small molecular photoswitches for protein modulation. *Org Biomol Chem* 16:8434–8445. <https://doi.org/10.1039/c8ob02157k>

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Tao Wang** is one of the master students supervised by the corresponding author Prof. Yong Tang since 2018. Her research interest is focusing on the application of optogenetic tools in Purinergic Signalling and Acupuncture Mechanism.